Sign In
Buy MRTX
$58.70
+0 (+0%)
At Close: Apr 19, 2024
Why Mirati Therapeutics Stock Is Skyrocketing This Week
04:40pm, Thursday, 09'th Jun 2022
The company presented great data at the American Society of Clinical Oncology annual meeting.
The Zacks Analyst Blog Highlights Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics
02:43pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.
Biotech Stock Roundup: BMY's Acquisition, REGN to Buy Libtayo & More
05:20pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
Mirati (MRTX) Up on Positive Data From NSCLC Study on Adagrasib
03:45pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
Mirati (MRTX) gains on positive results from an early stage KRYSTAL-1 study on experimental candidate adagrasib for lung cancer.
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022
02:14pm, Tuesday, 07'th Jun 2022 Benzinga
Upgrades
According to Jefferies, the prior rating for Arch Resources Inc (NYSE:ARCH) was changed from Hold to Buy. In the first quarter, Arch Resources showed an EPS of $13.08, compared to $0.40 from
Mirati (MRTX) Down 35.5% Since Last Earnings Report: Can It Rebound?
03:31pm, Friday, 03'rd Jun 2022 Zacks Investment Research
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mirati (MRTX) Down 23% on Mixed Data From Lung Cancer Study
06:39pm, Friday, 27'th May 2022 Zacks Investment Research
Mirati (MRTX) posts positive data from a phase II study evaluating its lung cancer candidate adagrasib. However, the drug caused side-effects in a large number of study participants.
Mirati (MRTX) Down 23% on Mixed Data From Lung Cancer Study
03:49pm, Friday, 27'th May 2022
Mirati (MRTX) posts positive data from a phase II study evaluating its lung cancer candidate adagrasib. However, the drug caused side-effects in a large number of study participants.
Even this pessimistic Bank of America strategist says the bear-rally bandwagon has room to charge ahead
12:43pm, Friday, 27'th May 2022 MarketWatch
Michael Hartnett said there will be a point to fade the S&P 500 rally. But not yet.
Expert Ratings for Mirati Therapeutics
05:05pm, Tuesday, 24'th May 2022 Benzinga
Within the last quarter, Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
5
0
2
0
0
Mirati (MRTX) Seeks EU Nod for Adagrasib to Treat Lung Cancer
06:17pm, Friday, 20'th May 2022 Zacks Investment Research
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.
Mirati (MRTX) Seeks EU Nod for Adagrasib to Treat Lung Cancer
03:48pm, Friday, 20'th May 2022
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.
Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2022
02:02pm, Friday, 20'th May 2022 Benzinga
Upgrades
For Telia Company AB (OTC:TLSNY), UBS upgraded the previous rating of Neutral to Buy. For the first quarter, Telia Company had an EPS of $0.05, compared to year-ago quarter EPS of $0.03. The
Analyst Ratings for Mirati Therapeutics
09:02pm, Thursday, 05'th May 2022 Benzinga
Within the last quarter, Mirati Therapeutics (NASDAQ:MRTX) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
0
2
0
0
Mirati (MRTX) Q1 Loss Wider Than Expected, Sales Beat
06:14pm, Thursday, 05'th May 2022 Zacks Investment Research
Mirati Therapeutics (MRTX) reports wider-than-expected Q1 loss while revenues beat the mark. MRTX plans to enter two new candidates into early-stage clinical studies in second-half 2022.
